Centro de Histoterapia Placentaria "Dr. Carlos Manuel Miyares Cao", 35 años de entrega a la Ciencia Cubana / "Dr. Carlos Miyares Cao" Placental Histotherapy Center, 35 years of dedication to Cuban Science

Introducción: La fundación del Centro de Histoterapia Placentaria, el 25 de abril de 1986, como resultado de la repercusión internacional por el nuevo método cubano del tratamiento del vitiligo con un medicamento obtenido de la placenta humana, descubierto por el doctor Carlos Manuel Miyares Cao, favoreció el desarrollo de las Ciencias Médicas en Cuba. Institución de prestigio, que arribó este 2021 a su Aniversario 35, y que ha obtenido un gran impacto en la salud y calidad de vida de personas con enfermedades dermatológicas como vitiligo, psoriasis y alopecia. Objetivo: Conocedores de la importancia de salvaguardar los hitos históricos como elementos imprescindibles en la trayectoria científico-social de una institución, nos propusimos exponer los componentes fundamentales que conforman este Centro de Histoterapia Placentaria e incentivar a las nuevas generaciones para continuar la labor investigativa que realiza este y la necesidad de preservar su historia. Material y Métodos: Se realizó una investigación histórico-bibliográfica de los documentos compilados que se conservan en la Biblioteca del Centro para poder fundamentar este artículo. Desarrollo: Se incluyen los aspectos esenciales que avalan la historia del Centro y la imbricación científico-social-humana en este del Dr. Carlos Manuel Miyares Cao. Conclusiones: Históricamente ofrecer toda la trayectoria de este Centro de Histoterapia Placentaria y su significación e importancia para la Ciencia Cubana, así como transmitir a especialistas, médicos y, en general, trabajadores de la salud, su destacada labor en la recuperación de graves enfermedades que aquejan a la población mundial(AU)

Introduction: As a result of the international repercussion of a new Cuban method for treating vitiligo with a drug obtained from human placenta, discovered by Dr. Carlos Manuel Miyares Cao, the Placental Histotherapy Center was founded on April 25, 1986 to support the development of Medical Sciences in Cuba. This prestigious institution, which arrived to its 35th Anniversary this year, has made a significant impact on the health and quality of life of people with dermatological diseases such as vitiligo, psoriasis and alopecia. Objective: Knowing the importance of safeguarding historical milestones as essential elements in the scientific and social trajectory of an institution, we intend to present the fundamental components that make up the Placental Histotherapy Center as well as to encourage new generations to continue the research work carried out in this center and the need to preserve its history. Material and Methods: A historical and bibliographical investigation of the documents preserved in the Library of the Center was carried out to base this article. Development: The essential aspects that support the history of the Center as well as the scientific, social and human involvement of Dr. Carlos Manuel Miyares Cao in this process are included. Conclusions: Our objective is to offer the entire trajectory of the Placental Histotherapy Center and its significance and importance for Cuban Science from a historical perspective as well as to inform specialists, doctors, and health workers in general about its outstanding work related to the recovery from serious diseases that afflict the world's population(AU)

Phototherapy

Abstract Of all the therapeutic options available in Dermatology, few of them have the history, effectiveness, and safety of phototherapy. Heliotherapy, NB-UVB, PUVA, and UVA1 are currently the most common types of phototherapy used. Although psoriasis is the most frequent indication, it is used for atopic dermatitis, vitiligo, cutaneous T-cell lymphoma, and cutaneous sclerosis, among others. Before indicating phototherapy, a complete patient assessment should be performed. Possible contraindications should be actively searched for and it is essential to assess whether the patient can come to the treatment center at least twice a week. One of the main method limitations is the difficulty that patients have to attend the sessions. This therapy usually occurs in association with other treatments: topical or systemic medications. Maintaining the regular monitoring of the patient is essential to identify and treat possible adverse effects. Phototherapy is recognized for its benefits and should be considered whenever possible.

Estratégias terapêuticas e atualizações no tratamento de vitiligo / Therapeutic strategies and updates for treatment of vitiligo

O vitiligo é uma desordem dermatológica complexa, cuja patogênese ainda não é totalmente esclarecida. Apesar de não apresentar complicações funcionais no organismo dos pacientes acometidos, o vitiligo pode resultar em um grande impacto psicossocial. Desse modo, é importante que os médicos saibam como conduzir o tratamento dessa patologia. O objetivo deste estudo foi documentar as terapias disponíveis para o tratamento do vitiligo, assim como apontar pesquisas que relataram a utilização dessas opções terapêuticas e os dados resultantes. As terapias abordadas foram corticoides tópicos e sistêmicos, fototerapia e fotoquimioterapias, antioxidantes, imunomoduladores, fenilalanina, despigmentação, procedimentos cirúrgicos e novas abordagens. A monoterapia parece ser menos eficaz no tratamento do vitiligo. A associação de medicação tópica e/ou sistêmica com o uso da fototerapia ultravioleta B de banda estreita parece ser o padrão-ouro para a repigmentação da pele dos pacientes. Medicamentos novos estão em estudo, porém sua eficácia e o estudo dos possíveis efeitos colaterais, principalmente a longo prazo, têm que ser melhores investigados. É necessário que o médico dermatologista, em conjunto com o paciente, escolha a melhor terapia dentre as disponíveis, de acordo com critérios clínicos e a possibilidade de acesso ao tratamento pelo portador. O acompanhamento e a abordagem por uma equipe multiprofissional também são importantes. (AU)

Vitiligo is a complex dermatological disorder, whose pathogenesis has not yet been fully elucidated. Although it does not present functional complications in the affected patients' body, vitiligo can result in a great psychosocial impact. Therefore, it is important that physicians know how to conduct its treatment. This study aimed at documenting the available therapies for the treatment of vitiligo, as well as pointing out studies reporting the use of these therapeutic options and their resulting data. The therapies addressed were topical and systemic corticosteroids, phototherapy, and photochemotherapies, antioxidants, immunomodulators, phenylalanine, depigmentation, surgical procedures, and new approaches. Monotherapy appears to be less effective in the treatment of vitiligo. The combination of topical and/or systemic medication with the use of narrowband ultraviolet B phototherapy seems to be the gold standard for the patients' skin repigmentation. New drugs are under study, but their effectiveness and study of possible side effects, especially in the long run, have to be better investigated. It is necessary that the dermatologist, together with the patient, choose the best therapy among those available, according to clinical criteria and the possibility of access to treatment by the patient. Monitoring and approach by a multiprofessional team is also important. (AU)

Evolución clínica en pacientes tratados con Esencias Florales de Bach y costo del tratamiento / Clinical Evolution and Cost of Treatment in Patients Treated with Bach Flower Essences

Introducción: La Medicina Natural y Tradicional constituye hoy en día una necesidad, no como opción terapéutica, sino por su valor intrínseco, al tratar al paciente de forma holística, además de su inocuidad y bajo costo. Objetivo: Evaluar la evolución clínica en pacientes tratados con Esencias florales de Bach y costo del tratamiento. Métodos: Se realizó un estudio de evaluación de la evolución de pacientes con diagnóstico clínico de Psoriasis, Vitíligo y Liquen plano, los cuales fueron tratados con Esencias florales de Bach en el período de marzo del 2016 a marzo del 2018, en Consulta Multidisciplinaria Dermatología- Medicina Natural Tradicional- Psicología, del Policlínico Docente Héroes del Moncada; del municipio de Cárdenas, Matanzas. Los datos fueron recopilados y procesados en el software Excel, atendiendo a variables demográficas, se tuvieron en cuenta los criterios de inclusión, exclusión y consentimiento informado de pacientes vírgenes de tratamiento convencional. Las esencias florales utilizadas fueron: Crab Apple, Willow, Verbain, Impatiems, Walnut, Cherry Plum, Sweet Chestnut, Chicory, Clematis, Beech, Star of Bethlehem, While Chestnut y Larch de forma oral y tópica. Resultados: En el sexo femenino predominó el Vitíligo y Psoriasis. La ansiedad estuvo presente en 17 pacientes, en cuanto a la evolución, 14 pacientes asintomáticos y 14 mejorados. El costo de las Esencias florales oral fue gratuito y el tópico muy bajo. Conclusiones: La evolución clínica fue favorable y el costo del tratamiento muy bajo, lo cual demostró la efectividad de la terapia floral en la muestra(AU)

Introduction: Natural and traditional medicine is nowadays a necessity, not as a therapeutic option, but because of its intrinsic value, since it allows to treat the patient holistically, in addition to its innocuousness and low cost. Objective: To assess the clinical evolution and cost of treatment in patients treated with Bach flower essences. Methods: A study was carried out to assess the evolution of patients with a clinical diagnosis of psoriasis, vitiligo and lichen planus, who were treated with Bach flower essences in the period from March 2016 to March 2018, at a multidisciplinary consultation of dermatology, traditional natural medicine and psychology from Héroes del Moncada Teaching Polyclinic in Cárdenas Municipality, Matanzas Province. The data were collected and processed in the EXCEL software, taking into account demographic variables, together with inclusion and exclusion criteria, as well as informed consent of patients who had not received any conventional treatment. The flower essences used, orally and topically, were crab apple, willow, verbain, impatiens, walnut, cherry plum, sweet chestnut, chicory, clematis, beech, star of Bethlehem, white chestnut and larch. Results: The female sex predominated in cases of vitiligo and psoriasis. Anxiety was present in seventeen patients. Regarding evolution, fourteen patients were asymptomatic and the same amount achieved improvement. The cost of the oral flower essences was free and that of the topical ones was very low. Conclusions: Clinical evolution was favorable and the cost of treatment was very low, which demonstrated the effectiveness of flower therapy in the sample studied(AU)

Consensus on the treatment of vitiligo - Brazilian Society of Dermatology

Abstract Background: Vitiligo is a muco-cutaneous, autoimmune, localized, or disseminated disease, which manifests through hypochromic or achromic macules, with loss in quality of life. The prevalence of vitiligo in Brazil was determined to be 0.54%. There is no on-label medication for its treatment. To date, no Brazilian consensus on the treatment of vitiligo had been written. Objectives: The objective of this group of Brazilian dermatologists with experience in the treatment of this disease was to reach a consensus on the clinical and surgical treatment of vitiligo, based on articles with the best scientific evidence. Methods: Seven dermatologists were invited, and each was assigned two treatment modalities to review. Each treatment (topical, systemic, and phototherapy) was reviewed by three experts. Two experts reviewed the surgical treatment. Subsequently, the coordinator compiled the different versions and drafted a text about each type of treatment. The new version was returned to all experts, who expressed their opinions and made suggestions for clarity. The final text was written by the coordinator and sent to all participants to prepare the final consensus. Results/Conclusion: The experts defined the following as standard treatments of vitiligo: the use of topical corticosteroids and calcineurin inhibitors for localized and unstable cases; corticosteroid minipulse in progressive generalized vitiligo; narrowband UVB phototherapy for extensive forms of the disease. Surgical modalities should be indicated for segmental and stable generalized vitiligo. Topical and systemic anti-JAK drugs are being tested, with promising results.

Histopathological findings in lesional and perilesional skin of vitiligo patients before and after narrow band ultraviolet B phototherapy

Background: Vitiligo is a skin disease with complex, multifactorial pathogenesis. Abnormalities in surrounding keratinocytes may cause melanocyte death due to deprivation of growth factors. Narrow band ultraviolet B (NB-UVB) is an effective therapeutic option especially in patients with generalized disease.Objective: The aim of this study was to identify histopathological changes in lesional and perilesional skin of vitiligo patients and the effect of NB-UVB therapy on them.Methods: Twenty patients were enrolled in this study. They received NB-UVB twice weekly on non-consecutive days for a total of 40 sessions. Skin biopsies from lesional and perilesional skin were obtained from each patient before and after therapy.Results: After therapy, 10% of patients showed excellent clinical response, 10% showed good response, 40% showed moderate response, 35% showed poor response and 5% showed progressive disease. Before therapy, 50% of patients showed a basal lymphocytic infiltrate with a perivascular lymphocytic infiltrate in both lesional and perilesional skin. 40% of them showed additional hydropic degeneration of lower epidermis with apoptotic keratinocytes in 20% of them. After therapy, these inflammatory changes were significantly reduced (p=0.04).Conclusion: NB-UVB is an effective method of treatment of vitiligo. This may be due to its immunosuppressive effects. Also, keratinocyte apoptosis may have a role in pathogenesis of vitiligo

Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo

Glycyrrhizin has been used clinically for several years due to its beneficial effect on immunoglobulin E (IgE)-induced allergic diseases, alopecia areata and psoriasis. In this study, glycyrrhizin, ultraviolet B light (UVB) or a combination of both were used to treat active-stage generalized vitiligo. One hundred and forty-four patients between the ages of 3 and 48 years were divided into three groups: group A received oral compound glycyrrhizin (OCG); group B received UVB applications twice weekly, and group C received OCG+UVB. Follow-ups were performed at 2, 4, and 6 months after the treatment was initiated. The Vitiligo Area Scoring Index (VASI) and the Vitiligo Disease Activity (VIDA) instrument were used to assess the affected body surface, at each follow-up. Results showed that 77.1, 75.0 and 87.5% in groups A, B and C, respectively, presented repigmentation of lesions. Responsiveness to therapy seemed to be associated with lesion location and patient compliance. Adverse events were limited and transient. This study showed that, although the three treatment protocols had positive results, OCG and UVB combination therapy was the most effective and led to improvement in disease stage from active to stable.

Photochemotherapy (PUVA) in psoriasis and vitiligo.

Phototherapy with photochemotherapy (PUVA) is a well‑known and well‑studied modality for the treatment of psoriasis, which involves systemic or topical administration of chemicals known as psoralens and administration of ultraviolet light in increasing dosages after requisite time gap. PUVA is also used in the treatment of widespread vitiligo with moderately good results, though it is being surpassed by ultraviolet B (UVB), which is equally or slightly more efficacious with fewer side effects. PUVA induces repigmentation by varying mechanisms such as stimulation of melanogenesis, immunomodulation and activation of growth factors, though the exact mechanism is still speculative. There are various studies evaluating the efficacy of PUVA in psoriasis as well as in vitiligo, either alone or in combination with other immunosuppressants like azathioprine and calcipotriene.

Vitiligo - Part 2 - classification, histopathology and treatment

In an unprecedented effort in the field of vitiligo, a global consensus resulted on a suggested new classification protocol for the disease. The main histopathological finding in vitiligo is the total absence of functioning melanocytes in the lesions, while the inflammatory cells most commonly found on the edges of the lesions are CD4+ and CD8+ T lymphocytes. Physical and pharmacological treatment strategies aim to control the autoimmune damage and stimulate melanocyte migration from the unaffected edges of lesions and the outer hair follicle root sheath to the affected skin; moreover, surgical treatments can be combined with topical and physical treatments.

Factores pronósticos en el vitíligo / Prognostic factors for vitiligo

INTRODUCCIÓN: el vitíligo es una enfermedad cutánea benigna caracterizada por manchas despigmentadas de bordes bien definidos. Se postula que se produce por un mecanismo autoinmunitario contra los melanocitos. OBJETIVO: valorar los factores pronósticos de vitíligo asociados a la evolución de pacientes con vitíligo moderado o intenso tratados con Melagenina Plus durante un año. MÉTODO: se efectuó un estudio de tipo retrospectivo en una serie consecutiva de 62 pacientes con vitíligo con un área afectada superior al 20 % que acudieron al Centro de Histoterapia Placentaria entre agosto de 2008 y agosto de 2010. La variable respuesta consistió en la respuesta al tratamiento a los 2 años de seguimiento. Se efectuó una regresión logística para determinar factores pronósticos. RESULTADOS: el grupo etario predominante fue el de 40 a 49 años (28,6 %). La mayoría de los pacientes fueron del sexo femenino (61,4 %). El color de la piel más observado fue el blanco. La categoría de superficie corporal más frecuente fue la de 20 a 39 %, con una media de 37,6 %. El tiempo de evolución tuvo una media de ,4 años. CONCLUSIONES: el tiempo de evolución y el área de superficie corporal fueron las únicas variables estadísticamente significativas al introducir el modelo de regresión logística. Ambas tuvieron una p asociada menor de 0,05.

INTRODUCTION: vitiligo is a benign skin disease characterized by depigmented patches of distinct borders. It is thought to be caused by an autoimmune reaction against melanocytes. OBJECTIVE: evaluate the prognostic factors for vitiligo associated with the evolution of patients with moderate or severe vitiligo treated with Melagenina Plus for a year. METHOD: a retrospective study was conducted of a consecutive series of 62 patients with vitiligo with an affected skin area above 20% who presented at the Placental Histotherapy Center from August 2008 to August 2010. The variable response consisted in the response to the treatment at 2 years of follow-up. A logistic regression analysis was performed to determine the prognostic factors. RESULTS: the predominant age group was 40-49 years (28.6%). Most patients were female (61.4%). The most common race was white. The most frequent body surface range was 20-39%, with a mean value of 37.6%. Average evolution time was 8.4 years. CONCLUSIONS: evolution time and body surface area were the only statistically significant variables found when the logistic regression model was applied. Both had a p value below 0.05.

Tratamiento homeopático para el vitiligo: un estudio piloto abierto observacional / Homoeopathic treatment of vitiligo: an open observational pilot study

Antecedentes: El vitiligo es un trastorno común de hipopigmentación que genera un impacto psicológico muy importante. En una clínica de atención ambulatoria en Bengala Occidental, India, se realizó una evaluación del tratamiento homeopático en individuos con vitiligo. Métodos: Se reclutaron 30 pacientes (edad media de 27 años; 57% femeninos) para un estudio piloto prospectivo abierto, y se manejaron con tratamiento homeopático individualizado durante seis meses. Se evaluó La eficacia del tratamiento a los tres y seis meses, utilizando el Índice de Puntuación del Área con Vitiligo (Vitiligo Area Scoring Index, VASI), la escala de la Comisión Europea de Vitiligo (Vitiligo European Task Force, VETF) y el Índice de Calidad de Vida en Dermatología (Dermatological Life Quality Index, DLQI), los cuales validaron el índice de mejoría tomando en cuenta el área, la intensidad, la extensión de La despigmentación de las lesiones de vitiligo y la calidad de vida (QoL). Resultados: Un total de 27 pacientes completaron el estudio; tres desertaron. Después de seis meses de tratamiento, la medida media de VASI mejoró significativamente en 0.1 unidades (p=0.003), de 0.8 (0.5, 1.5) a 0.7 (0.3, 0.8) en una escala de 0 (sin despigmentación) y 100 (completamente despigmentada). Del mismo modo, la media del VETF mejoró su puntuación por 2 unidades (p=0.0001), de 1 (0.1) a -1 (-1.0), y el marcador de estadificación varió de 1 (1.2) a 1 (0.1), p=0.002. La media de La puntuación total de DLQI disminuyó de 21 (17, 22) a 13.6 (10, 17), con variación de 7.4 (p=0.0001); dicha variación también fue corroborada por los componentes del DLQI. Conclusiones: El tratamiento homeopático individualizado se asoció con una mejoría significativa de las puntuaciones en VASI, VETF y DLQI. La premisa de que los efectos observados se deben a placebo se debe aclarar en futuros ensayos clínicos aleatorios doble ciego, precedidos por estudios de viabilidad.

Background: Vitiligo is a common hypopigmentation disorder with significant psychological impact. An evaluation of homeopathic treatment was performed in individuals with vitiligo in a hospital outpatient clinic in West Bengal, India. Methods: 30 participants (median age 27 years old, 57% female) were recruitedfor a prospective open-label pilot study and treated with individualized homeopathic medicines for six months. Efficacy was assessed after three months and six months using Vitiligo Area Scoring Index (VASI) score, Vitiligo European Task Force (VETF)score, and Dermatological Life Quality Index (DLQI) score, which are validatedoutcome measures evaluating the area, intensity, spread of depigmentation ofvitiligo lesions, and quality of life (QoL). Results: A total of 27 participants completed the trial; 3 dropped out. After 6 months of treatment, the median VASI total score improved significantly by 0.1 units (p=0.003), from 0.8 (0.5, 1.5) to 0.7 (0.3, 0.8) on a scale from 0 (no depigmentation) to 100 (completely depigmented). Similarly, the VETF median score improved by 2 units (p=0.0001) from 1 (0, 1) to -1 (-1, 0) and the staging score changed from 1 (1, 2) to 1 (0, 1), p=0.002. The total DLQI median score exhibited significant reduction from 21 (17, 22) to 13.6 (10, 17), change 7.4 (p=0.0001), as also did its components. Conclusions: Individualized homeopathictreatment associated with significant improvement of VASI, VETF and DLQI scores. The extent to which the observed effects were due to placebo needs clarificationin future randomized double-blind clinical studies preceded by feasibility studies.

Melanocitos en vitíligo y melanoma: una lección entre autoinmunidad e inmunidad tumoral / Melanocytes in vitiligo and melanoma: a lesson between autoimmunity and tumor immunity

Clásicamente, el vitiligo ha sido definido como una enfermedad de la piel en la cual los melanocitos (MC) son erradicados de una epidermis lesionada por células T autorreactivas con la presencia de moléculas del sistema inmune y otros componentes no inmunológicos que resultan en la pérdida de pigmento y lesiones cutáneas en el paciente. Anteriormente, la ausencia y daño en los MC ha sido asociado a mayor riesgo de cáncer de piel incluyendo melanoma. Sin embargo, en vitiligo se ha identificado la presencia de melanocitos 'no pigmentados', similar a individuos albinos, que aparentemente confieren mayor resistencia para el desarrollo de melanoma en estas personas. Estos hechos aparentemente contradictorios se complican aún más cuando los antigenos de los MC reconocidos por el sistema inmune durante la respuesta autoinmune o en la inmunidad antitumoral son los mismos en ambas enfermedades. Un análisis de las similitudes y diferencias entre la respuesta inmune contra MC observada en vitiligo y su rol en la inmunidad tumoral observada en melanoma, podría llevar a entender mejor el rol de estas células y al futuro desarrollo de nuevas terapias para ambas enfermedades.

Classically, vitiligo has been defined as a skin disease in which melanocytes (MC) are eradicated from lesional epidermis by MC- reactive T cells, as well as other non-immune and immune components, resulting in disfiguring loss of pigmento Moreover, the absence 01' damage on MC has frequently been associated to a major risk to develop skin cancer including melanoma. However, patients with vitiligo have also shown 'non-pigmented' MC in epidermis similar to individuals with albinism, and these cells are apparently conferring resistance of developing melanoma. These seemingly contradictory facts are further complicated because, the MC antigens which are immunologically recognized are shared for both diseases producing fairly different results. An analysis of the similarities and differences between the autoimmunity observed in vitiligo and the tumour immunity observed in melanoma might lead to a better understanding of the MC roles and the development of new therapies for both diseases.

Fototerapia ultravioleta B de banda angosta para el tratamiento de psoriasis, micosis fungoide y vitiligo / Phototherapy UVB Narrow Band treatment of Psoriasis, Mycosis fungoides and Vitiligo

Numerosos estudios han demostrado el efecto beneficioso de la radiación ultravioleta para el tratamiento de enfermedades cutáneas inflamatorias o linfoproliferativas. Objetivos. Determinar la respuesta a la terapia con ultravioleta B, banda angosta (UVB-ba) en psoriasis, micosis fungoide en estadio IA, IB y vitiligo, en el Servicio de Dermatología del Hospital Privado desde mayo de 2009 a enero de 2011. Correlacionar la dosis de energía total utilizada y el número total de sesiones con la respuesta alcanzada en cada patología. Describir las reacciones adversas, determinar las características demográficas de la población y comorbilidades asociadas en psoriasis y vitiligo. Material y métodos. Se diseñó un estudio prospectivo, descriptivo, analítico, observacional. Se incluyó a todos los pacientes que consultaron para iniciar UVB-ba. De los pacientes que consultaron para inicio de UVB-ba, pero no iniciaron o abandonaron, se realizó una encuesta para evaluar las causas. Se calculó la dosis acumulada y el número de sesiones al final del tratamiento. Resultados. En psoriasis consultaron 49, pero iniciaron 25 pacientes. El 56% de los pacientes mejoró su score PASI más del 50%. En micosis fungoide, consultaron 16 pacientes y comenzaron 14. El 78,55% logró mejoría clínica mayor al 50%. A pesar de que el número de pacientes con vitíligo es escaso (6), el 50% logró repigmentación entre el 26 y 65% de su superficie corporal, y un paciente mayor al 66%. Conclusiones. La fototerapia con UVB-ba constituye una buena opción terapéutica en nuestros pacientes con patologías cuyo uso ya ha sido establecido en estudios previos, como psoriasis, vitiligo y micosis fungoide...

Homoeopathic treatment of vitiligo: an open observational pilot study

Background: Vitiligo is a common hypopigmentation disorder with significant psychological impact. An evaluation of homeopathic treatment was performed in individuals with vitiligo in a hospital outpatient clinic in West Bengal, India. Methods: Thirty participants (median age 27 years old, 57% female) were recruited for a prospective open-label pilot study and treated with individualized homeopathic medicines for 6 months. Efficacy was assessed after 3 months and 6 months using Vitiligo Area Scoring Index (VASI) score, Vitiligo European Task Force (VETF) score, and Dermatological Life Quality Index (DLQI) score, which are validated outcome measures evaluating the area, intensity, spread of depigmentation of vitiligo lesions, and quality of life (QoL). Results: A total of 27 participants completed the trial; 3 dropped out. After 6 months of treatment, the median VASI total score improved significantly by 0.1 units (p=0.003), from 0.8 (0.5, 1.5) to 0.7 (0.3, 0.8) on a scale from 0 (no depigmentation) to 100 (completely depigmented). Similarly, the VETF median score improved by 2 units (p=0.0001) from 1 (0, 1) to –1 (–1, 0) and the staging score changed from 1 (1, 2) to 1 (0, 1), p=0.002. The total DLQI median score exhibited significant reduction from 21 (17, 22) to 13.6 (10, 17), change 7.4 (p=0.0001), as also did its components. Conclusions: Individualized homeopathic treatment associated with significant improvement of VASI, VETF and DLQI scores. The extent to which the observed effects were due to placebo needs clarification in future randomized double-blind clinical studies preceded by feasibility studies.

Introdução: Vitiligo é uma desordem de hipopigmentação de ocorrência comum, com impacto psicológico significativo. Foi avaliado o tratamento homeopático de indivíduos com vitiligo no ambulatório de um hospital em Bengala Ocidental, Índia. Métodos: Trinta participantes (idade mediana 27 anos, sendo 57% do gênero feminino) foram recrutados para o presente estudo piloto prospectivo aberto e tratados com medicamentos homeopáticos individualizados por 6 meses. A eficácia do tratamento foi avaliada aos 3 e 6 meses mediante Vitiligo Area Scoring Index (VASI) score, Vitiligo European Task Force (VETF), e Dermatological Life Quality Index (DLQI), que são medidas validadas de desfecho correspondendo à área, intensidade e disseminação da depigmentação causada por vitiligo, assim como a qualidade de vida (QV). Resultados: Um total de 27 participantes completou o estudo, sendo que 3 abandonaram. Depois de 6 meses de tratamento, a mediana do escore total do VASI apresentou melhora significativa de 0,1 unidade (p=0,003) passando de 0,8 (0,5, 1,5) para 0,7 (0,3, 0,8), numa escala de 0 (sem depigmentação) a 100 (depigmentação completa). De modo similar, a mediana do escore VETF de disseminação melhorou em 2 unidades (p=0,0001) de 1 (0, 1) a –1 (–1, 0), e o escore de estadiamento variou de 1 (1, 2) para 1 (0, 1), p=0,002. O escore total mediano de DLQI diminuiu de 21 (17, 22) a 13,6 (10, 17), com uma variação de 7,4 (p=0,0001); variação também foi constatada nos componentes de DLQI. Conclusões: O tratamento homeopático individualizado se associou com melhora significativa nos escores de VASI, VETF e DLQI. A parte dos efeitos possivelmente devida a efeito placebo precisa ser determinada em futuros estudos clínicos randomizados e duplo cego, após a realização de estudos de factibilidade.

Action of topical mometasone on the pigmented halos of micrografting in patients with vitiligo / Ação da mometasona tópica nos halos pigmentares de microenxertia em vitiligo

BACKGROUND: Vitiligo is a prevalent skin pigmentation disorder worldwide. The treatments available still offer limited results to some patients. For patients with clinically stable vitiligo, melanocyte transplantation is an appropriate treatment option, and the technique of autologous punch grafting shows good repigmentation. OBJECTIVE: To evaluate the effect of topical mometasone on the halos of repigmentation after autologous punch grafting in patients with clinically stable vitiligo. METHODS: Between 2009 and 2010, 11 patients with clinically stable vitiligo (7 generalized, 2 focal and 2 segmental) underwent autologous punch grafting in the achromic patches. According to the clinical type of vitiligo, patients were instructed to use the corticosteroid ointment during 6 months, only on a few grafted lesions. In the first month, the mometasone ointment was used twice a day and after that just once. They were reassessed 1, 3 and 6 months after the procedure. Grafted halos were photographed and recorded using the software fotofinder. After 6 months, all the treated and untreated areas of the repigmentation halos were measured and analyzed comparatively. RESULTS: The median area of the repigmentation halos after 6 months of treatment with mometasone was larger (25,96 mm² ) than the one of the untreated halos (13,86 mm² ), showing a statistically significant difference (p = 0,026). CONCLUSION: In this study, the use of mometasone ointment increased the area of the repigmentation halos after punch grafting. However, this should be further investigated in larger samples in order to validate this positive action in the treatment of stable vitiligo.

FUNDAMENTOS: Vitiligo é um transtorno de pigmentação freqüente na população mundial. Seu tratamento ainda oferece resultados limitados em alguns pacientes. Nos casos de vitiligo estável clinicamente, o transplante de melanócitos tornase uma opção terapêutica, sendo a técnica de enxertos autólogos por punch empregada com boa resposta na repigmentação. OBJETIVOS: Estudar a ação do corticoesteróide tópico mometasona sobre halos de repigmentação após enxertos autólogos por punch em pacientes com vitiligo estável clinicamente. MÉTODOS: Entre 2009 e 2010, 11 pacientes com vitiligo estável (7 do tipo generalizado, 2 focal e 2 segmentar) foram submetidos a enxertos autólogos por punch nas máculas acrômicas. Conforme o tipo clínico do vitiligo, os pacientes eram orientados a aplicar pomada de mometasona por 6 meses em lesões enxertadas selecionadas individualmente. No primeiro mês, a aplicação era 2 vezes ao dia e nos demais, apenas uma vez ao dia. Eram reavaliados nos meses 1, 3 e 6 após enxertos cujos halos eram fotografados e registrados pelo software fotofinder. No fim do 6̊mês, todas as áreas dos halos de repigmentação com e sem mometasona foram mensuradas e analisadas comparativamente. RESULTADOS: A mediana da área dos halos de repigmentação após os 6 meses com mometasona foi superior (25,96 mm² ) comparada àquela sem mometasona (13,86 mm² ), com diferença estatisticamente significante (p=0,026). CONCLUSÃO: Em nossa casuística, o uso da mometasona tópica determinou incremento dos halos de repigmentação após enxertia. A amplificação da amostra se faz necessária em estudos posteriores a fim de ratificar esta ação positiva da mometasona no tratamento do vitiligo estável.

Efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B no vitiligo / Application purposes of HeNe L.A.S.E.R. and ultraviolet B in vitiligo

INTRODUÇÃO: O vitiligo é uma doença crônica despigmentante da pele, ocasionada pela perda funcional dos melanócitos da epiderme. Este estudo teve como objetivo comparar os efeitos da aplicação do L.A.S.E.R. HeNe e do ultravioleta B em pacientes com vitiligo. MÉTODO: Foram selecionados 22 pacientes (11 mulheres e 11 homens), com idade entre 12 e 60 anos (31,68 ± 16,29). Os pacientes foram distribuídos aleatoriamente, de acordo com a ordem de comparecimento no serviço e foram divididos randomicamente em dois grupos: o grupo A (n = 12), submetido à aplicação do L.A.S.E.R. HeNe, para o qual a técnica utilizada foi a pontual com aproximadamente 3 cm de distância entre cada ponto, perpendicularmente à pele, e o grupo B (n = 10), exposto ao Ultravioleta B, aplicado de forma perpendicular com 10 cm de afastamento da pele do paciente. Para mensuração da área tratada, utilizou-se o programa AUTOCAD 2002, no qual foi delimitada a borda da mácula em fotos tiradas no início e no fim do tratamento. RESULTADOS: Inicialmente, no grupo A, a área era de 4,87 cm² ± 3,70 e, após a aplicação, foi de 4,15 cm² ± 2,89, com diferença média de 0,72 cm² (1,89). No grupo B, verificou-se que antes da aplicação a média era de 5,36 cm² ± 6,36 e, a após a aplicação, foi de 4,43 cm² ± 5,17, com diferença média de 0,92 cm² ± 1,29. CONCLUSÃO: Ambos os aparelhos obtiveram resultados significativos na redução da mácula, com maior redução no grupo da ultravioleta.

INTRODUCTION: The Vitiligo is a chronic depigmentation illness of the skin caused by loss of functional melanocytes in the epidermis. This study's objective was to compare the effects of applying L.A.S.E.R. HeNe and ultraviolet B in patients with vitiligo. METHOD: 22 patients (11 women and 11 men) aged 12-60 years (31,68 ± 16,29) were selected. Patients were randomly assigned, according to the order of attendance at the service and were divided randomly into two groups: group A (n = 12) subjected to the application of L.A.S.E.R. HeNe, where the technique used was punctual with about 3 cm distance between each point, perpendicular to the skin, and group B (n = 10) exposed to Ultraviolet B applied perpendicular 10 cm away from the patient's skin. For measurement of the treated area it was used the AUTOCAD program, which was bounded to the edge of the stain on photos taken at the beginning and at the end of treatment. RESULTS: Initially, in group A the area was 4,87 cm² ± 3,70, and after application it was 4,15 cm² ± 2,89, with an average difference of 0,72 cm² ± 1,89. In group B it was noted that before applying the average was 5,36 cm² ± 6,36, and after application it was 4,43 cm² ± 5,17, with average difference of 0,92 cm² ± 1,29. CONCLUSION: Both devices achieved significant results in reducing the stain, with a greater reduction in the group of ultraviolet.

Experiencia en el tratamiento del vitiligo utilizando UVB pulsado de banda ancha y tacrolimus tópico / Broad band targeted UVB and topical tacrolimus treating localized vitiligo: our experience

Introducción: El tratamiento del vitiligo es prolongado y los resultados suelen ser desalentadores. Existen terapias que se han utilizado con resultados aceptables, como PUVA (psoraleno asociado a radiación UVA) y UVB de banda angosta (UVBnb).Recientemente se ha comenzado a utilizar con éxito el excimer láser para el tratamiento del vitiligo localizado. Existe evidencia de que el UVB pulsado de banda ancha tendría efectos biológicos similares a este último. Material y método. Se realizó un estudio prospectivo, descriptivo y observacional con 15 pacientes, 12 con vitiligo generalizado, 2 con vitiligo localizado y un paciente con vitiligo segmentario. Todos ellos habían realizado tratamiento previo con tacrolimus tópico con escasa respuesta. Se inició tratamiento combinado con tacrolimus tópico dos veces por día y UVB de banda ancha pulsado dos sesiones por semana, durante 30 sesiones. Resultados. Todos los pacientes mostraron distintos niveles de repigmentación: 12 pacientes alcanzaron el 75% o más de repigmentación, 2 pacientes entre el 50 y el 75%, y un solo paciente no mostró ninguna mejoría (paciente con vitiligo segmentario).Conclusión. La combinación del tacrolimus tópico y el UVB de banda ancha pulsado es una buena alternativa para el tratamiento del vitiligo.